Recently, palbociclib, an FDA-approved CDK4/6 inhibitor for treating metastatic breast cancer, has been demonstrated to show antitumor effects by inhibiting tumor growth in acral melanoma and mucosal melanoma with CDK4 amplifications in patient-derived xenograft models [27,52,111]. Here, CDK4 is linked to neoplasm.